Steve Schonfeld’s Immuneering IMRX Stock Holding History

Steve Schonfeld’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,900	Closed	-$83.8K	–	2790
2026 Q1	$83.8K	Buy	+15,900	New	+$81.5K	﹤0.01%	1914

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Steve Schonfeld's IMRX Position: Q2 2026 in Review

Steve Schonfeld sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 15,900 shares — an estimated $83.8K sold.

Steve Schonfeld first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $83.8K in Q1 2026. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Steve Schonfeld reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
Steve Schonfeld sold 15,900 Immuneering shares in Q2 2026, an estimated $83.8K.
Steve Schonfeld first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
Steve Schonfeld's Immuneering position peaked at $83.8K in Q1 2026.
111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.